It’s unlikely Vas Narasimhan will rank at the top of any 2018 compensation lists for Big Pharma CEOs. But the Novartis helmsman is definitely on a whole new pay scale compared to what he earned as a drug development chief.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,700+ biopharma pros who read Endpoints News by email every day.Free Subscription